| Literature DB >> 22032400 |
Stephen R Marder1, Bryan Roth, Patrick F Sullivan, Edward M Scolnick, Eric J Nestler, Mark A Geyer, Daniel R Welnberger, Maria Karayiorgou, Alessandro Guidotti, Jay Gingrich, Schahram Akbarian, Robert W Buchanan, Jeffrey A Lieberman, P Jeffrey Conn, Stephen J Haggarty, Amanda J Law, Brian Campbell, John H Krystal, Bita Moghaddam, Akira Sawa, Akira Saw, Marc G Caron, Susan R George, John A Allen, Michelle Solis.
Abstract
Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22032400 PMCID： PMC3787879 DOI： 10.1111/j.1749-6632.2011.06216.x
Source DB: PubMed Journal: Ann N Y Acad Sci ISSN： 0077-8923 Impact factor: 5.691